Ronny Drapkin, MD, PhD - Perelman School of Medicine, University of Pennsylvania - Director, Penn Ovarian Cancer Research Center

Ronny Drapkin

MD, PhD

Perelman School of Medicine, University of Pennsylvania

Director, Penn Ovarian Cancer Research Center

Philadelphia, Pennsylvania | United States

Main Specialties: Pathology-Anatomic & Clinical

ORCID logohttps://orcid.org/0000-0002-6912-6977

Ronny Drapkin, MD, PhD - Perelman School of Medicine, University of Pennsylvania - Director, Penn Ovarian Cancer Research Center

Ronny Drapkin

MD, PhD

Introduction

Primary Affiliation: Perelman School of Medicine, University of Pennsylvania - Philadelphia, Pennsylvania , United States

Specialties:

Research Interests:

Education

Jan 2001 - Aug 2006
Dana Farber Cancer Institute
Postdoctoral Research with David Livingston (NAS)
Cancer Biology
Jul 1998 - Jun 2001
Brigham and Womens Hospital
Residency in Anatomic Pathology
Pathology
Jan 1992 - May 1998
Rutgers Robert Wood Johnson Medical School
MD
MD-PhD program
Jan 1992 - May 1996
Rutgers Robert Wood Johnson Medical School
PhD with Danny Reinberg (HHMI, NAS)
Aug 1986 - May 1990
Brandeis University
BA, senior honors thesis with James Haber (NAS)
Biochemistry

Experience

Aug 2006 - Jan 2015
Dana Farber Cancer Institute
Assistant/Associate Professor
Medical Oncology
Feb 2015
University of Pennsylvania
Director, Ovarian Cancer Research Center
Obstetrics & Gynecology

Publications

260Publications

4636Reads

4Profile Views

5489PubMed Central Citations

Innervation of cervical carcinoma is mediated by cancer-derived exosomes.

Gynecol Oncol 2019 07 17;154(1):228-235. Epub 2019 Apr 17.

Sanford Research, Cancer Biology and Immunotherapy Group, 2301 East 60th St north, Sioux Falls, SD 57104, USA. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00908258193114
Publisher Site
http://dx.doi.org/10.1016/j.ygyno.2019.04.651DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6589362PMC
July 2019
15 Reads
3.774 Impact Factor

Early Loss of Histone H2B Monoubiquitylation Alters Chromatin Accessibility and Activates Key Immune Pathways That Facilitate Progression of Ovarian Cancer.

Cancer Res 2019 02 18;79(4):760-772. Epub 2018 Dec 18.

Penn Ovarian Cancer Research Center, Department of Obstetrics and Gynecology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-18-2297DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6377833PMC
February 2019
102 Reads
9.329 Impact Factor

A miRNA-Mediated Approach to Dissect the Complexity of Tumor-Initiating Cell Function and Identify miRNA-Targeting Drugs.

Stem Cell Reports 2019 Jan;12(1):122-134

Rogel Cancer Center, The University of Michigan, Michigan Medicine, Ann Arbor, MI, USA; Department of Obstetrics and Gynecology, The University of Michigan, Michigan Medicine, Ann Arbor, MI, USA; Department of Pathology, The University of Michigan, Michigan Medicine, Ann Arbor, MI, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.stemcr.2018.12.002DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6335585PMC
January 2019
4 Reads

Expression of the POTE gene family in human ovarian cancer.

Sci Rep 2018 Nov 20;8(1):17136. Epub 2018 Nov 20.

Eppley Institute for Cancer Research, University of Nebraska Medical Center, Omaha, NE, 68198-6805, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41598-018-35567-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6244393PMC
November 2018
30 Reads
5.080 Impact Factor

Precious GEMMs: emergence of faithful models for ovarian cancer research.

J Pathol 2018 Jun 2;245(2):129-131. Epub 2018 Apr 2.

Penn Ovarian Cancer Research Center, Department of Obstetrics and Gynecology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/path.5065
Publisher Site
http://dx.doi.org/10.1002/path.5065DOI Listing
June 2018
8 Reads
7.430 Impact Factor

Epigenetic remodeling regulates transcriptional changes between ovarian cancer and benign precursors.

JCI Insight 2016 Aug;1(13)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; Harvard Medical School, Boston, Massachusetts, USA.; Penn Ovarian Cancer Research Center, Department of Obstetrics and Gynecology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1172/jci.insight.87988DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5017158PMC
August 2016
50 Reads
3 Citations

Epigenetic remodeling regulates transcriptional changes between ovarian cancer and benign precursors.

Elias KM, Emori MM, Westerling T, Long H, Budina-Kolomets A, Li F, MacDuffie E, Davis MR, Holman A, Lawney B, Freedman ML, Quackenbush J, Brown M, Drapkin R, JCI insight, 2016, vol. 1, no. 13, 2016

http://europepmc.org/abstract/med/27617304

View Article
August 2016
12 Reads

Mutant p53 regulates ovarian cancer transformed phenotypes through autocrine matrix deposition.

Iwanicki MP, Chen HY, Iavarone C, Zervantonakis IK, Muranen T, Novak M, Ince TA, Drapkin R, Brugge JS, JCI insight, 2016, vol. 1, no. 10, 2016

http://europepmc.org/abstract/med/27482544

View Article
July 2016
11 Reads

YAP induces high-grade serous carcinoma in fallopian tube secretory epithelial cells.

Oncogene 2016 04 14;35(17):2247-65. Epub 2015 Sep 14.

Olson Center for Women's Health, Department of Obstetrics/Gynecology, University of Nebraska Medical Center, Omaha, NE, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/onc.2015.288DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4791205PMC
April 2016
10 Reads
13 Citations
8.460 Impact Factor

Development of a prosaposin-derived therapeutic cyclic peptide that targets ovarian cancer via the tumor microenvironment.

Sci Transl Med 2016 Mar;8(329):329ra34

Vascular Biology Program, Boston Children's Hospital, Boston, MA 02115, USA. Department of Surgery, Harvard Medical School, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1126/scitranslmed.aad5653DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6261358PMC
March 2016
103 Reads
5 Citations
15.843 Impact Factor

Development of a prosaposin-derived therapeutic cyclic peptide that targets ovarian cancer via the tumor microenvironment.

Wang S, Blois A, El Rayes T, Liu JF, Hirsch MS, Gravdal K, Palakurthi S, Bielenberg DR, Akslen LA, Drapkin R, Mittal V, Watnick RS, Science translational medicine, 2016, vol. 8, no. 329, pp. 329ra34, 2016

http://europepmc.org/abstract/med/26962158

View Article
March 2016
16 Reads

It's Totally Tubular....Riding The New Wave of Ovarian Cancer Research.

Cancer Res 2016 Jan 15;76(1):10-7. Epub 2015 Dec 15.

Department of Obstetrics and Gynecology, Ovarian Cancer Research Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-15-1382DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4703449PMC
January 2016
22 Reads
23 Citations
9.330 Impact Factor

Platinum and PARP Inhibitor Resistance Due to Overexpression of MicroRNA-622 in BRCA1-Mutant Ovarian Cancer.

Cell Rep 2016 Jan 7;14(3):429-439. Epub 2016 Jan 7.

Division of Genomic Stability and DNA Repair, Department of Radiation Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S22111247150148
Publisher Site
http://dx.doi.org/10.1016/j.celrep.2015.12.046DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4731274PMC
January 2016
87 Reads
10 Citations
7.210 Impact Factor

F1000Prime Recommendation

Authors:
Ronny Drapkin

Drapkin R: F1000Prime Recommendation of [Bester AC et al., Cell 2011,145(3):435-46]. Faculty of 1000, 14 Aug 2013; DOI: 10.3410/f.10858958.793481415.

http://f1000.com/prime/10858958#eval793481415

View Article
January 2016
11 Reads

Platinum and PARP Inhibitor Resistance Due to Overexpression of MicroRNA-622 in BRCA1-Mutant Ovarian Cancer.

Choi YE, Meghani K, Brault ME, Leclerc L, He YJ, Day TA, Elias KM, Drapkin R, Weinstock DM, Dao F, Shih KK, Matulonis U, Levine DA, Konstantinopoulos PA, Chowdhury D, Cell reports, 2016, vol. 14, no. 3, pp. 429-439, 2016

http://europepmc.org/abstract/med/26774475

View Article
January 2016
12 Reads

Elafin: a double agent in breast and ovarian cancer.

Oncoscience 2015 17;2(10):793-4. Epub 2015 Sep 17.

Ovarian Cancer Research Center, Department of Obstetrics and Gynecology, Basser Center for BRCA, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4671923PMC
http://dx.doi.org/10.18632/oncoscience.246DOI Listing
December 2015
9 Reads

Long Noncoding RNA Ceruloplasmin Promotes Cancer Growth by Altering Glycolysis.

Cell Rep 2015 Dec 10;13(11):2395-2402. Epub 2015 Dec 10.

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; Center for RNA Interference and Non-Coding RNAs, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.celrep.2015.11.047DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4691557PMC
December 2015
137 Reads
25 Citations
7.210 Impact Factor

Long Noncoding RNA Ceruloplasmin Promotes Cancer Growth by Altering Glycolysis.

Rupaimoole R, Lee J, Haemmerle M, Ling H, Previs RA, Pradeep S, Wu SY, Ivan C, Ferracin M, Dennison JB, Millward NM, Nagaraja AS, Gharpure KM, McGuire M, Sam N, Armaiz-Pena GN, Sadaoui NC, Rodriguez-Aguayo C, Calin GA, Drapkin RI, Cell reports, 2015, vol. 13, no. 11, pp. 2395-2402

http://europepmc.org/abstract/med/26686630

View Article
December 2015
11 Reads

Creation of a Human Secretome: A Novel Composite Library of Human Secreted Proteins: Validation Using Ovarian Cancer Gene Expression Data and a Virtual Secretome Array.

Clin Cancer Res 2015 Nov 5;21(21):4960-9. Epub 2015 May 5.

Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts. Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-14-3173DOI Listing
November 2015
29 Reads
7 Citations
8.722 Impact Factor

GATA3 expression in gestational trophoblastic tissues and tumours.

Histopathology 2015 Nov 12;67(5):636-44. Epub 2015 May 12.

Department of Pathology, Women's and Perinatal Pathology Division, Brigham and Women's Hospital, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/his.12681DOI Listing
November 2015
73 Reads
3.453 Impact Factor

Corrigendum: Whole-genome characterization of chemoresistant ovarian cancer.

Nature 2015 Nov 21;527(7578):398. Epub 2015 Oct 21.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nature15716DOI Listing
November 2015
46 Reads
2 Citations
42.351 Impact Factor

PEPCK Coordinates the Regulation of Central Carbon Metabolism to Promote Cancer Cell Growth.

Mol Cell 2015 Nov 17;60(4):571-83. Epub 2015 Oct 17.

Department of Pharmacological Sciences, Stony Brook University, Stony Brook, NY 11794, USA; Department of Pathology, Stony Brook University School of Medicine, Stony Brook, NY 11794, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.molcel.2015.09.025DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4656111PMC
November 2015
42 Reads
25 Citations
14.020 Impact Factor

Role of miR-182 in response to oxidative stress in the cell fate of human fallopian tube epithelial cells.

Oncotarget 2015 Nov;6(36):38983-98

Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.5493DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4770751PMC
November 2015
23 Reads
5 Citations
6.360 Impact Factor

Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer.

Bowtell DD, Böhm S, Ahmed AA, Aspuria PJ, Bast RC Jr, Beral V, Berek JS, Birrer MJ, Blagden S, Bookman MA, Brenton JD, Chiappinelli KB, Martins FC, Coukos G, Drapkin R, Edmondson R, Fotopoulou C, Gabra H, Galon J, Gourley C, Nature reviews. Cancer, 2015, vol. 15, no. 11, pp. 668-679

http://europepmc.org/abstract/med/26493647

View Article
November 2015
13 Reads

GATA3 expression in gestational trophoblastic tissues and tumours.

Mirkovic J, Elias K, Drapkin R, Barletta JA, Quade B, Hirsch MS, Histopathology, 2015, vol. 67, no. 5, pp. 636-644

http://europepmc.org/abstract/med/25753145

View Article
November 2015
13 Reads

Corrigendum: Whole-genome characterization of chemoresistant ovarian cancer.

Patch AM, Christie EL, Etemadmoghadam D, Garsed DW, George J, Fereday S, Nones K, Cowin P, Alsop K, Bailey PJ, Kassahn KS, Newell F, Quinn MC, Kazakoff S, Quek K, Wilhelm-Benartzi C, Curry E, Leong HS, Australian Ovarian Cancer Study Group, Hamilton A, Nature, 2015, vol. 527, no. 7578, pp. 398

http://europepmc.org/abstract/med/26503049

View Article
November 2015
13 Reads

GATA3 Is a Sensitive and Specific Marker of Benign and Malignant Mesonephric Lesions in the Lower Female Genital Tract.

Am J Surg Pathol 2015 Oct;39(10):1411-9

*Department of Pathology, Division of Women's and Perinatal Pathology, Brigham and Women's Hospital †Harvard Medical School ‡Department of Medical Oncology, Dana Farber Cancer Institute ∥Department of Pathology, Massachusetts General Hospital, Boston, MA §Department of Pathology, Belfast Health and Social Care Trust, Belfast, Northern Ireland, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PAS.0000000000000471DOI Listing
October 2015
46 Reads
4 Citations
5.145 Impact Factor

Tumor-Targeted Synergistic Blockade of MAPK and PI3K from a Layer-by-Layer Nanoparticle.

Clin Cancer Res 2015 Oct 1;21(19):4410-9. Epub 2015 Jun 1.

Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts. Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts. Institute for Soldier Nanotechnologies, Massachusetts Institute of Technology, Cambridge, Massachusetts.

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/content/early/2015/08/
Web Search
http://clincancerres.aacrjournals.org/cgi/doi/10.1158/1078-0
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-15-0013DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4624301PMC
October 2015
67 Reads
10 Citations
8.722 Impact Factor

Stathmin 1 and p16(INK4A) are sensitive adjunct biomarkers for serous tubal intraepithelial carcinoma.

Gynecol Oncol 2015 Oct 20;139(1):104-11. Epub 2015 Jul 20.

Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA; Department of Pathology, Division of Women's and Perinatal Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2015.07.100DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4586950PMC
October 2015
23 Reads
13 Citations
3.774 Impact Factor

Beyond genomics: critical evaluation of cell line utility for ovarian cancer research.

Gynecol Oncol 2015 Oct 29;139(1):97-103. Epub 2015 Aug 29.

Dana-Farber Cancer Institute, Boston, MA 02115, USA; Harvard Medical School, Boston, MA 02115, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2015.08.017DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4587360PMC
October 2015
26 Reads
18 Citations
3.774 Impact Factor

Tumor-Targeted Synergistic Blockade of MAPK and PI3K from a Layer-by-Layer Nanoparticle.

Dreaden EC, Kong YW, Morton SW, Correa S, Choi KY, Shopsowitz KE, Renggli K, Drapkin R, Yaffe MB, Hammond PT, Clinical cancer research : an official journal of the American Association for Cancer Research, 2015, vol. 21, no. 19, pp. 4410-4419

http://europepmc.org/abstract/med/26034127

View Article
October 2015
13 Reads

GATA3 Is a Sensitive and Specific Marker of Benign and Malignant Mesonephric Lesions in the Lower Female Genital Tract.

Howitt BE, Emori MM, Drapkin R, Gaspar C, Barletta JA, Nucci MR, McCluggage WG, Oliva E, Hirsch MS, The American journal of surgical pathology, 2015, vol. 39, no. 10, pp. 1411-1419

http://europepmc.org/abstract/med/26135559

View Article
October 2015
16 Reads

Cis-eQTL analysis and functional validation of candidate susceptibility genes for high-grade serous ovarian cancer.

Authors:
Kate Lawrenson Qiyuan Li Siddhartha Kar Ji-Heui Seo Jonathan Tyrer Tassja J Spindler Janet Lee Yibu Chen Alison Karst Ronny Drapkin Katja K H Aben Hoda Anton-Culver Natalia Antonenkova Helen Baker Elisa V Bandera Yukie Bean Matthias W Beckmann Andrew Berchuck Maria Bisogna Line Bjorge Natalia Bogdanova Louise A Brinton Angela Brooks-Wilson Fiona Bruinsma Ralf Butzow Ian G Campbell Karen Carty Jenny Chang-Claude Georgia Chenevix-Trench Anne Chen Zhihua Chen Linda S Cook Daniel W Cramer Julie M Cunningham Cezary Cybulski Agnieszka Dansonka-Mieszkowska Joe Dennis Ed Dicks Jennifer A Doherty Thilo Dörk Andreas du Bois Matthias Dürst Diana Eccles Douglas T Easton Robert P Edwards Ursula Eilber Arif B Ekici Peter A Fasching Brooke L Fridley Yu-Tang Gao Aleksandra Gentry-Maharaj Graham G Giles Rosalind Glasspool Ellen L Goode Marc T Goodman Jacek Grownwald Patricia Harrington Philipp Harter Hanis Nazihah Hasmad Alexander Hein Florian Heitz Michelle A T Hildebrandt Peter Hillemanns Estrid Hogdall Claus Hogdall Satoyo Hosono Edwin S Iversen Anna Jakubowska Paul James Allan Jensen Bu-Tian Ji Beth Y Karlan Susanne Kruger Kjaer Linda E Kelemen Melissa Kellar Joseph L Kelley Lambertus A Kiemeney Camilla Krakstad Jolanta Kupryjanczyk Diether Lambrechts Sandrina Lambrechts Nhu D Le Alice W Lee Shashi Lele Arto Leminen Jenny Lester Douglas A Levine Dong Liang Jolanta Lissowska Karen Lu Jan Lubinski Lene Lundvall Leon F A G Massuger Keitaro Matsuo Valerie McGuire John R McLaughlin Heli Nevanlinna Ian McNeish Usha Menon Francesmary Modugno Kirsten B Moysich Steven A Narod Lotte Nedergaard Roberta B Ness Mat Adenan Noor Azmi Kunle Odunsi Sara H Olson Irene Orlow Sandra Orsulic Rachel Palmieri Weber Celeste L Pearce Tanja Pejovic Liisa M Pelttari Jennifer Permuth-Wey Catherine M Phelan Malcolm C Pike Elizabeth M Poole Susan J Ramus Harvey A Risch Barry Rosen Mary Anne Rossing Joseph H Rothstein Anja Rudolph Ingo B Runnebaum Iwona K Rzepecka Helga B Salvesen Joellen M Schildkraut Ira Schwaab Thomas A Sellers Xiao-Ou Shu Yurii B Shvetsov Nadeem Siddiqui Weiva Sieh Honglin Song Melissa C Southey Lara Sucheston Ingvild L Tangen Soo-Hwang Teo Kathryn L Terry Pamela J Thompson Agnieszka Timorek Ya-Yu Tsai Shelley S Tworoger Anne M van Altena Els Van Nieuwenhuysen Ignace Vergote Robert A Vierkant Shan Wang-Gohrke Christine Walsh Nicolas Wentzensen Alice S Whittemore Kristine G Wicklund Lynne R Wilkens Yin-Ling Woo Xifeng Wu Anna H Wu Hannah Yang Wei Zheng Argyrios Ziogas Alvaro Monteiro Paul D Pharoah Simon A Gayther Matthew L Freedman

Nat Commun 2015 Sep 22;6:8234. Epub 2015 Sep 22.

Department of Medical Oncology, The Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/ncomms9234DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4580986PMC
September 2015
167 Reads
7 Citations
10.742 Impact Factor

Cell-type-specific enrichment of risk-associated regulatory elements at ovarian cancer susceptibility loci.

Coetzee SG, Shen HC, Hazelett DJ, Lawrenson K, Kuchenbaecker K, Tyrer J, Rhie SK, Levanon K, Karst A, Drapkin R, Ramus SJ, Ovarian Cancer Association Consortium, The Consortium of Investigators of Modifiers of BRCA1/2, Couch FJ, Offit K, Chenevix-Trench G, Monteiro AN, Antoniou A, Freedman M, Coetze

http://europepmc.org/abstract/med/25804953

View Article
July 2015
7 Reads

Whole-genome characterization of chemoresistant ovarian cancer.

Nature 2015 May;521(7553):489-94

1] Peter MacCallum Cancer Centre, East Melbourne, Victoria 3002, Australia [2] Department of Pathology, University of Melbourne, Parkville, Victoria 3052, Australia [3] Sir Peter MacCallum Cancer Centre Department of Oncology, University of Melbourne, Parkville, Victoria 3052, Australia [4] Ovarian Cancer Action Research Centre, Department of Surgery and Cancer, Imperial College London, London W12 0HS, UK [5] Department of Biochemistry and Molecular Biology, University of Melbourne, Parkville, Victoria 3052, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nature14410DOI Listing
May 2015
121 Reads
193 Citations
42.351 Impact Factor

Whole-genome characterization of chemoresistant ovarian cancer.

Patch AM, Christie EL, Etemadmoghadam D, Garsed DW, George J, Fereday S, Nones K, Cowin P, Alsop K, Bailey PJ, Kassahn KS, Newell F, Quinn MC, Kazakoff S, Quek K, Wilhelm-Benartzi C, Curry E, Leong HS, Australian Ovarian Cancer Study Group, Hamilton A, Mileshkin L, Au-Yeung G, Kennedy C, Hung J, Chi

http://europepmc.org/abstract/med/26017449

View Article
May 2015
12 Reads

Creation of a human Secretome: Novel Composite Library of Human Secreted Proteins: Validation using Ovarian Cancer Gene Expression Data and Virtual Secretome Array.

Vathipadiekal V, Wang XV, Wei W, Waldron L, Drapkin R, Gillette M, Skates SJ, Birrer MJ, Clinical cancer research : an official journal of the American Association for Cancer Research, 2015

http://europepmc.org/abstract/med/25944803

View Article
May 2015
20 Reads

Combined therapy with thrombospondin-1 type I repeats (3TSR) and chemotherapy induces regression and significantly improves survival in a preclinical model of advanced stage epithelial ovarian cancer.

FASEB J 2015 Feb 13;29(2):576-88. Epub 2014 Nov 13.

Department of Biomedical Sciences, University of Guelph, Guelph, Ontario, Canada; and

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1096/fj.14-261636DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4314231PMC
February 2015
38 Reads
14 Citations
5.043 Impact Factor

Drug-induced death signaling strategy rapidly predicts cancer response to chemotherapy.

Montero J, Sarosiek KA, DeAngelo JD, Maertens O, Ryan J, Ercan D, Piao H, Horowitz NS, Berkowitz RS, Matulonis U, Jänne PA, Amrein PC, Cichowski K, Drapkin R, Letai A, Cell, 2015, vol. 160, no. 5, pp. 977-989

http://europepmc.org/abstract/med/25723171

View Article
February 2015
33 Reads

Combined therapy with thrombospondin-1 type I repeats (3TSR) and chemotherapy induces regression and significantly improves survival in a preclinical model of advanced stage epithelial ovarian cancer.

Russell S, Duquette M, Liu J, Drapkin R, Lawler J, Petrik J, FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2015, vol. 29, no. 2, pp. 576-588

http://europepmc.org/abstract/med/25395453

View Article
February 2015
10 Reads

Elafin: a double agent in breast and ovarian cancer.

Feng Y, Doberstein K, Drapkin R, Oncoscience, 2015, vol. 2, no. 10, pp. 793-794

http://europepmc.org/abstract/med/26682248

View Article
January 2015
28 Reads

Cis-eQTL analysis and functional validation of candidate susceptibility genes for high-grade serous ovarian cancer.

Lawrenson K, Li Q, Kar S, Seo JH, Tyrer J, Spindler TJ, Lee J, Chen Y, Karst A, Drapkin R, Aben KK, Anton-Culver H, Antonenkova N, Australian Ovarian Cancer Study Group, Baker H, Bandera EV, Bean Y, Beckmann MW, Berchuck A, Bisogna M, Bjorge L, Bogdanova N, Brinton LA, Brooks-Wilson A, Bruinsma F, B

http://europepmc.org/abstract/med/26391404

View Article
January 2015
14 Reads

Elafin drives poor outcome in high-grade serous ovarian cancers and basal-like breast tumors.

Labidi-Galy SI, Clauss A, Ng V, Duraisamy S, Elias KM, Piao HY, Bilal E, Davidowitz RA, Lu Y, Badalian-Very G, Györffy B, Kang UB, Ficarro S, Ganesan S, Mills GB, Marto JA, Drapkin R, Oncogene, 2015, vol. 34, no. 3, pp. 373-383

http://europepmc.org/abstract/med/24469047

View Article
January 2015
13 Reads

An in-tumor genetic screen reveals that the BET bromodomain protein, BRD4, is a potential therapeutic target in ovarian carcinoma.

Baratta MG, Schinzel AC, Zwang Y, Bandopadhayay P, Bowman-Colin C, Kutt J, Curtis J, Piao H, Wong LC, Kung AL, Beroukhim R, Bradner JE, Drapkin R, Hahn WC, Liu JF, Livingston DM, Proceedings of the National Academy of Sciences of the United States of America, 2015, vol. 112, no. 1, pp. 232-237

http://europepmc.org/abstract/med/25535366

View Article
January 2015
17 Reads

CD151-α3β1 integrin complexes suppress ovarian tumor growth by repressing slug-mediated EMT and canonical Wnt signaling.

Oncotarget 2014 Dec;5(23):12203-17

Department of Pharmacology and Nutritional Science, Department of Molecular and Cellular Biochemistry, and Markey Cancer Center, University of Kentucky, Lexington, KY.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4322965PMC
http://dx.doi.org/10.18632/oncotarget.2622DOI Listing
December 2014
31 Reads
14 Citations
6.360 Impact Factor

CD151-α3β1 integrin complexes suppress ovarian tumor growth by repressing slug-mediated EMT and canonical Wnt signaling.

Baldwin LA, Hoff JT, Lefringhouse J, Zhang M, Jia C, Liu Z, Erfani S, Jin H, Xu M, She QB, van Nagell JR, Wang C, Chen L, Plattner R, Kaetzel DM, Luo J, Lu M, West D, Liu C, Ueland FR, Drapkin R, Zhou BP, Yang XH, Oncotarget, 2014, vol. 5, no. 23, pp. 12203-12217

http://europepmc.org/abstract/med/25356755

View Article
December 2014
12 Reads

FOXO3a loss is a frequent early event in high-grade pelvic serous carcinogenesis.

Levanon K, Sapoznik S, Bahar-Shany K, Brand H, Shapira-Frommer R, Korach J, Hirsch MS, Roh MH, Miron A, Liu JF, Vena N, Ligon AH, Fotheringham S, Bailey D, Flavin RJ, Birrer MJ, Drapkin RI, Oncogene, 2014, vol. 33, no. 35, pp. 4424-4432

http://europepmc.org/abstract/med/24077281

View Article
August 2014
12 Reads

The hormonal composition of follicular fluid and its implications for ovarian cancer pathogenesis.

Reprod Biol Endocrinol 2014 Jul 6;12:60. Epub 2014 Jul 6.

Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, 450 Brookline Avenue, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1477-7827-12-60DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4105128PMC
July 2014
28 Reads
7 Citations
2.410 Impact Factor

Highlights from the 2014 American Association for Cancer Research Annual Meeting.

Gynecol Oncol 2014 Jul;134(1):3-5

View Article

Download full-text PDF

Source
July 2014
13 Reads
3.774 Impact Factor

Use of CA125 and HE4 serum markers to predict ovarian cancer in elevated-risk women.

Karlan BY, Thorpe J, Watabayashi K, Drescher CW, Palomares M, Daly MB, Paley P, Hillard P, Andersen MR, Anderson G, Drapkin R, Urban N, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Onco

http://europepmc.org/abstract/med/24789859

View Article
July 2014
13 Reads

Highlights from the 2014 American Association for Cancer Research Annual Meeting.

Bowtell DD, Drapkin R, Gynecologic oncology, 2014, vol. 134, no. 1, pp. 3-5

http://europepmc.org/abstract/med/25089320

View Article
July 2014
12 Reads

Mesenchymal gene program-expressing ovarian cancer spheroids exhibit enhanced mesothelial clearance.

Davidowitz RA, Selfors LM, Iwanicki MP, Elias KM, Karst A, Piao H, Ince TA, Drage MG, Dering J, Konecny GE, Matulonis U, Mills GB, Slamon DJ, Drapkin R, Brugge JS, The Journal of clinical investigation, 2014, vol. 124, no. 6, pp. 2611-2625

http://europepmc.org/abstract/med/24762435

View Article
June 2014
8 Reads

Endosalpingiosis as it relates to tubal, ovarian and serous neoplastic tissues: an immunohistochemical study of tubal and Müllerian antigens.

Gynecol Oncol 2014 Feb 13;132(2):316-21. Epub 2013 Dec 13.

Laboratory of Gynecologic Oncology, Division of Gynecologic Oncology, Brigham & Women's Hospital, Harvard Medical School, Boston, MA, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2013.12.007DOI Listing
February 2014
63 Reads
2 Citations
3.774 Impact Factor

Cyclin E1 deregulation occurs early in secretory cell transformation to promote formation of fallopian tube-derived high-grade serous ovarian cancers.

Cancer Res 2014 Feb 23;74(4):1141-52. Epub 2013 Dec 23.

Authors' Affiliations: Department of Medical Oncology; Center for Molecular Oncologic Pathology, Dana-Farber Cancer Institute; Harvard Medical School; Department of Pathology, Division of Cytogenetics; Department of Pathology, Division of Women's and Perinatal Pathology, Brigham and Women's Hospital, Boston, Massachusetts; Peter MacCallum Cancer Centre, East Melbourne; Department of Oncology, Peter MacCallum Cancer Centre; Departments of Pathology and Biochemistry and Molecular Biology, University of Melbourne, Melbourne, Victoria, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-13-2247DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4517944PMC
February 2014
33 Reads
23 Citations
9.330 Impact Factor

Prior appendectomy does not protect against subsequent development of malignant or borderline mucinous ovarian neoplasms.

Gynecol Oncol 2014 Feb 14;132(2):328-33. Epub 2013 Dec 14.

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA; Brigham and Women's Hospital, Department of Pathology, Boston, MA, USA; Brigham and Women's Hospital, Division of Women's and Perinatal Pathology, Boston, MA, USA. Electronic address:

View Article

Download full-text PDF

Source
http://research4.dfci.harvard.edu/drapkin_lab/PDFs/EliasGynO
Web Search
http://linkinghub.elsevier.com/retrieve/pii/S009082581301375
Publisher Site
http://dx.doi.org/10.1016/j.ygyno.2013.12.011DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3929430PMC
February 2014
28 Reads
2 Citations
3.774 Impact Factor

Endosalpingiosis as it relates to tubal, ovarian and serous neoplastic tissues: an immunohistochemical study of tubal and Mullerian antigens.

Esselen KM, Ng SK, Hua Y, White M, Jimenez CA, Welch WR, Drapkin R, Berkowitz RS, Ng SW, Gynecologic oncology, 2014, vol. 132, no. 2, pp. 316-321

http://europepmc.org/abstract/med/24333360

View Article
February 2014
13 Reads

Cyclin E1 deregulation occurs early in secretory cell transformation to promote formation of fallopian tube-derived high-grade serous ovarian cancers.

Karst AM, Jones PM, Vena N, Ligon AH, Liu JF, Hirsch MS, Etemadmoghadam D, Bowtell DD, Drapkin R, Cancer research, 2014, vol. 74, no. 4, pp. 1141-1152

http://europepmc.org/abstract/med/24366882

View Article
February 2014
12 Reads

In vivo multiplexed interrogation of amplified genes identifies GAB2 as an ovarian cancer oncogene.

Proc Natl Acad Sci U S A 2014 Jan 2;111(3):1102-7. Epub 2014 Jan 2.

Department of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.1311909111DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3903232PMC
January 2014
92 Reads
19 Citations
9.810 Impact Factor

The hormonal composition of follicular fluid and its implications for ovarian cancer pathogenesis.

Emori MM, Drapkin R, Reproductive biology and endocrinology : RB&E, 2014, vol. 12, pp. 60

http://europepmc.org/abstract/med/24997727

View Article
January 2014
11 Reads

In vivo multiplexed interrogation of amplified genes identifies GAB2 as an ovarian cancer oncogene.

Dunn GP, Cheung HW, Agarwalla PK, Thomas S, Zektser Y, Karst AM, Boehm JS, Weir BA, Berlin AM, Zou L, Getz G, Liu JF, Hirsch M, Vazquez F, Root DE, Beroukhim R, Drapkin R, Hahn WC, Proceedings of the National Academy of Sciences of the United States of America, 2014, vol. 111, no. 3, pp. 1102-1107

http://europepmc.org/abstract/med/24385586

View Article
January 2014
11 Reads

Transformation of the fallopian tube secretory epithelium leads to high-grade serous ovarian cancer in Brca;Tp53;Pten models.

Cancer Cell 2013 Dec;24(6):751-65

Department of Medical Oncology, Center for Molecular Oncologic Pathology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA; Division of Women's and Perinatal Pathology, Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccr.2013.10.013DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3917315PMC
December 2013
72 Reads
121 Citations
23.523 Impact Factor

Transformation of the fallopian tube secretory epithelium leads to high-grade serous ovarian cancer in Brca;Tp53;Pten models.

Perets R, Wyant GA, Muto KW, Bijron JG, Poole BB, Chin KT, Chen JY, Ohman AW, Stepule CD, Kwak S, Karst AM, Hirsch MS, Setlur SR, Crum CP, Dinulescu DM, Drapkin R, Cancer cell, 2013, vol. 24, no. 6, pp. 751-765

http://europepmc.org/abstract/med/24332043

View Article
December 2013
11 Reads

HE4 transcription- and splice variants-specific expression in endometrial cancer and correlation with patient survival.

Int J Mol Sci 2013 Nov 18;14(11):22655-77. Epub 2013 Nov 18.

Department of Biomedical Science, School of Medicine, Mercer University, Savannah, GA 31404, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/ijms141122655DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3856083PMC
November 2013
31 Reads
7 Citations
2.862 Impact Factor

Coming into focus: the nonovarian origins of ovarian cancer.

Dubeau L, Drapkin R, Annals of oncology : official journal of the European Society for Medical Oncology / ESMO, 2013, vol. 24 Suppl 8, pp. viii28-viii35

http://europepmc.org/abstract/med/24131966

View Article
November 2013
11 Reads

Modeling High-Grade Serous Carcinoma: How Converging Insights into Pathogenesis and Genetics are Driving Better Experimental Platforms.

Front Oncol 2013 26;3:217. Epub 2013 Aug 26.

Department of Medical Oncology, Harvard Medical School, Dana-Farber Cancer Institute , Boston, MA , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fonc.2013.00217DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3752910PMC
August 2013
21 Reads
14 Citations

Promoter methylation of the SALL2 tumor suppressor gene in ovarian cancers.

Mol Oncol 2013 Jun 12;7(3):419-27. Epub 2012 Dec 12.

Department of Microbiology and Immunobiology, Harvard Medical School, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.molonc.2012.11.005DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5528472PMC
June 2013
23 Reads
10 Citations
5.331 Impact Factor

Human epididymis protein 4 is up-regulated in gastric and pancreatic adenocarcinomas.

Hum Pathol 2013 May 16;44(5):734-42. Epub 2012 Oct 16.

Nashville VA Medical Center, Vanderbilt University School of Medicine, Nashville, TN 37232, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.humpath.2012.07.017DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3556378PMC
May 2013
10 Reads
8 Citations
2.770 Impact Factor

Human epididymis protein 4 is up-regulated in gastric and pancreatic adenocarcinomas.

O'Neal RL, Nam KT, LaFleur BJ, Barlow B, Nozaki K, Lee HJ, Kim WH, Yang HK, Shi C, Maitra A, Montgomery E, Washington MK, El Rifai W, Drapkin RI, Goldenring JR, Human pathology, 2013, vol. 44, no. 5, pp. 734-742

http://europepmc.org/abstract/med/23084584

View Article
May 2013
13 Reads

HE4 (WFDC2) Promotes Tumor Growth in Endometrial Cancer Cell Lines.

Int J Mol Sci 2013 Mar 15;14(3):6026-43. Epub 2013 Mar 15.

Department of Biomedical Science, School of Medicine, Mercer University, Savannah, GA 31404, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/ijms14036026DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3634435PMC
March 2013
29 Reads
10 Citations
2.862 Impact Factor

The polyoma virus large T binding protein p150 is a transcriptional repressor of c-MYC.

PLoS One 2012 28;7(9):e46486. Epub 2012 Sep 28.

Department of Microbiology and Immunobiology, Harvard Medical School, Boston, Massachusetts, United States of America.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0046486PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3460914PMC
February 2013
27 Reads
6 Citations
3.234 Impact Factor

There is a need for routine peritoneal cytology at RRSO.

Gynecol Oncol 2013 Jan 9;128(1):149-150. Epub 2012 Oct 9.

Department of Gynaecological Oncology, Gynaecological Cancer Research Centre, EGA Institute for Women's Health, University College London, Maple House, 149 Tottenham Court Road, London W1T 7DN, UK. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2012.09.031DOI Listing
January 2013
37 Reads
3.774 Impact Factor

Stathmin-1 expression as a complement to p16 helps identify high-grade cervical intraepithelial neoplasia with increased specificity.

Am J Surg Pathol 2013 Jan;37(1):89-97

Department of Pathology, Division of Women's and Perinatal Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PAS.0b013e3182753f5aDOI Listing
January 2013
61 Reads
8 Citations
5.145 Impact Factor

HE4 transcription- and splice variants-specific expression in endometrial cancer and correlation with patient survival.

Jiang SW, Chen H, Dowdy S, Fu A, Attewell J, Kalogera E, Drapkin R, Podratz K, Broaddus R, Li J, International journal of molecular sciences, 2013, vol. 14, no. 11, pp. 22655-22677

http://europepmc.org/abstract/med/24252907

View Article
January 2013
15 Reads

HE4 (WFDC2) Promotes Tumor Growth in Endometrial Cancer Cell Lines.

Li J, Chen H, Mariani A, Chen D, Klatt E, Podratz K, Drapkin R, Broaddus R, Dowdy S, Jiang SW, International journal of molecular sciences, 2013, vol. 14, no. 3, pp. 6026-6043

http://europepmc.org/abstract/med/23502467

View Article
January 2013
16 Reads

There is a need for routine peritoneal cytology at RRSO.

Manchanda R, Drapkin R, Menon U, Gynecologic oncology, 2013, vol. 128, no. 1, pp. 149-150

http://europepmc.org/abstract/med/23063757

View Article
January 2013
17 Reads

Stathmin-1 expression as a complement to p16 helps identify high-grade cervical intraepithelial neoplasia with increased specificity.

Howitt BE, Nucci MR, Drapkin R, Crum CP, Hirsch MS, The American journal of surgical pathology, 2013, vol. 37, no. 1, pp. 89-97

http://europepmc.org/abstract/med/23211296

View Article
January 2013
9 Reads

Prognostically relevant gene signatures of high-grade serous ovarian carcinoma.

Verhaak RG, Tamayo P, Yang JY, Hubbard D, Zhang H, Creighton CJ, Fereday S, Lawrence M, Carter SL, Mermel CH, Kostic AD, Etemadmoghadam D, Saksena G, Cibulskis K, Duraisamy S, Levanon K, Sougnez C, Tsherniak A, Gomez S, Onofrio R, Gabriel S, Chin L, Zhang N, Spellman PT, Zhang Y, Akbani R, Hoadley K

http://europepmc.org/abstract/med/23257362

View Article
January 2013
21 Reads

Profiles of genomic instability in high-grade serous ovarian cancer predict treatment outcome.

Wang ZC, Birkbak NJ, Culhane AC, Drapkin R, Fatima A, Tian R, Schwede M, Alsop K, Daniels KE, Piao H, Liu J, Etemadmoghadam D, Miron A, Salvesen HB, Mitchell G, DeFazio A, Quackenbush J, Berkowitz RS, Iglehart JD, Bowtell DD, Australian Ovarian Cancer Study Group, Matulonis UA, Clinical cancer resea

http://europepmc.org/abstract/med/22912389

View Article
October 2012
12 Reads

Primary culture and immortalization of human fallopian tube secretory epithelial cells.

Nat Protoc 2012 Sep 30;7(9):1755-64. Epub 2012 Aug 30.

Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nprot.2012.097DOI Listing
September 2012
31 Reads
28 Citations

Targeted tumor-penetrating siRNA nanocomplexes for credentialing the ovarian cancer oncogene ID4.

Ren Y, Cheung HW, von Maltzhan G, Agrawal A, Cowley GS, Weir BA, Boehm JS, Tamayo P, Karst AM, Liu JF, Hirsch MS, Mesirov JP, Drapkin R, Root DE, Lo J, Fogal V, Ruoslahti E, Hahn WC, Bhatia SN, Science translational medicine, 2012, vol. 4, no. 147, pp. 147ra112

http://europepmc.org/abstract/med/22896676

View Article
August 2012
11 Reads

ErbB2, EphrinB1, Src kinase and PTPN13 signaling complex regulates MAP kinase signaling in human cancers.

PLoS One 2012 18;7(1):e30447. Epub 2012 Jan 18.

Cancer Biology Research Center, Sanford Research/University of South Dakota, Sioux Falls, South Dakota, United States of America.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0030447PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3261204PMC
July 2012
20 Reads
11 Citations
3.234 Impact Factor

High throughput interrogation of somatic mutations in high grade serous cancer of the ovary.

PLoS One 2011 8;6(9):e24433. Epub 2011 Sep 8.

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0024433PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3169600PMC
June 2012
25 Reads
19 Citations
3.234 Impact Factor

The role of peritoneal cytology at risk-reducing salpingo-oophorectomy (RRSO) in women at increased risk of familial ovarian/tubal cancer.

Gynecol Oncol 2012 Feb 20;124(2):185-91. Epub 2011 Oct 20.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2011.10.017DOI Listing
February 2012
11 Reads
2 Citations
3.774 Impact Factor

Correlation of serum HE4 with tumor size and myometrial invasion in endometrial cancer.

Gynecol Oncol 2012 Feb 28;124(2):270-5. Epub 2011 Oct 28.

Division of Gynecologic Surgery, Mayo Clinic, Rochester, MN, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2011.10.025DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3913473PMC
February 2012
22 Reads
12 Citations
3.774 Impact Factor

Correlation of serum HE4 with tumor size and myometrial invasion in endometrial cancer.

Kalogera E, Scholler N, Powless C, Weaver A, Drapkin R, Li J, Jiang SW, Podratz K, Urban N, Dowdy SC, Gynecologic oncology, 2012, vol. 124, no. 2, pp. 270-275

http://europepmc.org/abstract/med/22037318

View Article
February 2012
20 Reads

The polyoma virus large T binding protein p150 is a transcriptional repressor of c-MYC.

Sung CK, Yim H, Gu H, Li D, Andrews E, Duraisamy S, Li C, Drapkin R, Benjamin T, PloS one, 2012, vol. 7, no. 9, pp. e46486

http://europepmc.org/abstract/med/23029531

View Article
January 2012
12 Reads

Genome wide DNA copy number analysis of serous type ovarian carcinomas identifies genetic markers predictive of clinical outcome.

Engler DA, Gupta S, Growdon WB, Drapkin RI, Nitta M, Sergent PA, Allred SF, Gross J, Deavers MT, Kuo WL, Karlan BY, Rueda BR, Orsulic S, Gershenson DM, Birrer MJ, Gray JW, Mohapatra G, PloS one, 2012, vol. 7, no. 2, pp. e30996

http://europepmc.org/abstract/med/22355333

View Article
January 2012
12 Reads

ErbB2, EphrinB1, Src kinase and PTPN13 signaling complex regulates MAP kinase signaling in human cancers.

Vermeer PD, Bell M, Lee K, Vermeer DW, Wieking BG, Bilal E, Bhanot G, Drapkin RI, Ganesan S, Klingelhutz AJ, Hendriks WJ, Lee JH, PloS one, 2012, vol. 7, no. 1, pp. e30447

http://europepmc.org/abstract/med/22279592

View Article
January 2012
12 Reads

Angiogenic mRNA and microRNA gene expression signature predicts a novel subtype of serous ovarian cancer.

Bentink S, Haibe-Kains B, Risch T, Fan JB, Hirsch MS, Holton K, Rubio R, April C, Chen J, Wickham-Garcia E, Liu J, Culhane A, Drapkin R, Quackenbush J, Matulonis UA, PloS one, 2012, vol. 7, no. 2, pp. e30269

http://europepmc.org/abstract/med/22348002

View Article
January 2012
9 Reads

The new face of ovarian cancer modeling: better prospects for detection and treatment.

F1000 Med Rep 2011 1;3:22. Epub 2011 Nov 1.

Department of Medical Oncology, Center for Molecular Oncologic Pathology, Dana-Farber Cancer Institute 450 Brookline Avenue, Boston, MA 02215 USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3410/M3-22DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3206707PMC
November 2011
22 Reads
10 Citations

Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy.

Ni Chonghaile T, Sarosiek KA, Vo TT, Ryan JA, Tammareddi A, Moore Vdel G, Deng J, Anderson KC, Richardson P, Tai YT, Mitsiades CS, Matulonis UA, Drapkin R, Stone R, Deangelo DJ, McConkey DJ, Sallan SE, Silverman L, Hirsch MS, Carrasco DR, Letai A, Science (New York, N.Y.), 2011, vol. 334, no. 6059,

http://europepmc.org/abstract/med/22033517

View Article
November 2011
14 Reads

Stathmin 1, a marker of PI3K pathway activation and regulator of microtubule dynamics, is expressed in early pelvic serous carcinomas.

Gynecol Oncol 2011 Oct 17;123(1):5-12. Epub 2011 Jun 17.

Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2011.05.021DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3171572PMC
October 2011
26 Reads
23 Citations
3.774 Impact Factor

Stathmin 1, a marker of PI3K pathway activation and regulator of microtubule dynamics, is expressed in early pelvic serous carcinomas.

Karst AM, Levanon K, Duraisamy S, Liu JF, Hirsch MS, Hecht JL, Drapkin R, Gynecologic oncology, 2011, vol. 123, no. 1, pp. 5-12

http://europepmc.org/abstract/med/21683992

View Article
October 2011
14 Reads

Rethinking ovarian cancer: recommendations for improving outcomes.

Vaughan S, Coward JI, Bast RC Jr, Berchuck A, Berek JS, Brenton JD, Coukos G, Crum CC, Drapkin R, Etemadmoghadam D, Friedlander M, Gabra H, Kaye SB, Lord CJ, Lengyel E, Levine DA, McNeish IA, Menon U, Mills GB, Nephew KP, Oza AM, Sood AK, Stronach EA, Walczak H, Bowtell DD, Balkwill FR, Nature revie

http://europepmc.org/abstract/med/21941283

View Article
October 2011
16 Reads

Ovarian cancer pathogenesis: a model in evolution.

J Oncol 2010 6;2010:932371. Epub 2009 Sep 6.

Department of Medical Oncology, Center for Molecular Oncologic Pathology, Dana-Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2010/932371DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2739011PMC
July 2011
23 Reads
80 Citations

Systematic investigation of genetic vulnerabilities across cancer cell lines reveals lineage-specific dependencies in ovarian cancer.

Cheung HW, Cowley GS, Weir BA, Boehm JS, Rusin S, Scott JA, East A, Ali LD, Lizotte PH, Wong TC, Jiang G, Hsiao J, Mermel CH, Getz G, Barretina J, Gopal S, Tamayo P, Gould J, Tsherniak A, Stransky N, Luo B, Ren Y, Drapkin R, Bhatia SN, Mesirov JP, Garraway LA, Meyerson M, Lander ES, Root DE, Hahn WC

http://europepmc.org/abstract/med/21746896

View Article
July 2011
18 Reads

A comprehensive analysis of PAX8 expression in human epithelial tumors.

Am J Surg Pathol 2011 Jun;35(6):816-26

Department of Pathology, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PAS.0b013e318216c112DOI Listing
June 2011
50 Reads
45 Citations
5.145 Impact Factor

A comprehensive analysis of PAX8 expression in human epithelial tumors.

Laury AR, Perets R, Piao H, Krane JF, Barletta JA, French C, Chirieac LR, Lis R, Loda M, Hornick JL, Drapkin R, Hirsch MS, The American journal of surgical pathology, 2011, vol. 35, no. 6, pp. 816-826

http://europepmc.org/abstract/med/21552115

View Article
June 2011
14 Reads

Modeling high-grade serous ovarian carcinogenesis from the fallopian tube.

Proc Natl Acad Sci U S A 2011 May 18;108(18):7547-52. Epub 2011 Apr 18.

Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.1017300108DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3088633PMC
May 2011
39 Reads
94 Citations
9.810 Impact Factor

Ex vivo culture of primary human fallopian tube epithelial cells.

J Vis Exp 2011 May 9(51). Epub 2011 May 9.

Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3791/2728DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3197121PMC
May 2011
9 Reads
11 Citations

Modeling high-grade serous ovarian carcinogenesis from the fallopian tube.

Karst AM, Levanon K, Drapkin R, Proceedings of the National Academy of Sciences of the United States of America, 2011, vol. 108, no. 18, pp. 7547-7552

http://europepmc.org/abstract/med/21502498

View Article
May 2011
14 Reads

STICS, SCOUTs and p53 signatures; a new language for pelvic serous carcinogenesis.

Front Biosci (Elite Ed) 2011 Jan 1;3:625-34. Epub 2011 Jan 1.

Division of Women's and Perinatal Pathology, Brigham and Women's Hospital, Department of Cell Biology, Harvard Medical School, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
January 2011
34 Reads
26 Citations

STICS, SCOUTs and p53 signatures; a new language for pelvic serous carcinogenesis.

Mehra K, Mehrad M, Ning G, Drapkin R, McKeon FD, Xian W, Crum CP, Frontiers in bioscience (Elite edition), 2011, vol. 3, pp. 625-634

http://europepmc.org/abstract/med/21196340

View Article
January 2011
13 Reads

Ex vivo culture of primary human fallopian tube epithelial cells.

Fotheringham S, Levanon K, Drapkin R, Journal of visualized experiments : JoVE, 2011

http://europepmc.org/abstract/med/21610668

View Article
January 2011
19 Reads

53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers.

Bouwman P, Aly A, Escandell JM, Pieterse M, Bartkova J, van der Gulden H, Hiddingh S, Thanasoula M, Kulkarni A, Yang Q, Haffty BG, Tommiska J, Blomqvist C, Drapkin R, Adams DJ, Nevanlinna H, Bartek J, Tarsounas M, Ganesan S, Jonkers J, Nature structural & molecular biology, 2010, vol. 17, no. 6, pp.

http://europepmc.org/abstract/med/20453858

View Article
June 2010
13 Reads

PAX8 reliably distinguishes ovarian serous tumors from malignant mesothelioma.

Am J Surg Pathol 2010 May;34(5):627-35

Department of Pathology Section, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PAS.0b013e3181da7687DOI Listing
May 2010
64 Reads
42 Citations
5.145 Impact Factor

PAX8 reliably distinguishes ovarian serous tumors from malignant mesothelioma.

Laury AR, Hornick JL, Perets R, Krane JF, Corson J, Drapkin R, Hirsch MS, The American journal of surgical pathology, 2010, vol. 34, no. 5, pp. 627-635

http://europepmc.org/abstract/med/20414098

View Article
May 2010
7 Reads

An activated ErbB3/NRG1 autocrine loop supports in vivo proliferation in ovarian cancer cells.

Sheng Q, Liu X, Fleming E, Yuan K, Piao H, Chen J, Moustafa Z, Thomas RK, Greulich H, Schinzel A, Zaghlul S, Batt D, Ettenberg S, Meyerson M, Schoeberl B, Kung AL, Hahn WC, Drapkin R, Livingston DM, Liu JF, Cancer cell, 2010, vol. 17, no. 3, pp. 298-310

http://europepmc.org/abstract/med/20227043

View Article
March 2010
14 Reads

Primary ex vivo cultures of human fallopian tube epithelium as a model for serous ovarian carcinogenesis.

Levanon K, Ng V, Piao HY, Zhang Y, Chang MC, Roh MH, Kindelberger DW, Hirsch MS, Crum CP, Marto JA, Drapkin R, Oncogene, 2010, vol. 29, no. 8, pp. 1103-1113

http://europepmc.org/abstract/med/19935705

View Article
February 2010
5 Reads

Overexpression of elafin in ovarian carcinoma is driven by genomic gains and activation of the nuclear factor kappaB pathway and is associated with poor overall survival.

Clauss A, Ng V, Liu J, Piao H, Russo M, Vena N, Sheng Q, Hirsch MS, Bonome T, Matulonis U, Ligon AH, Birrer MJ, Drapkin R, Neoplasia (New York, N.Y.), 2010, vol. 12, no. 2, pp. 161-172

http://europepmc.org/abstract/med/20126474

View Article
February 2010
6 Reads

Ovarian cancer pathogenesis: a model in evolution.

Karst AM, Drapkin R, Journal of oncology, 2010, vol. 2010, pp. 932371

http://europepmc.org/abstract/med/19746182

View Article
January 2010
12 Reads

Does the fimbria have an embryologic origin distinct from that of the rest of the fallopian tube?

Fertil Steril 2008 Nov 18;90(5):2008.e5-8. Epub 2008 Mar 18.

Department of Surgery, Division of Gynecology, Children's Hospital Boston, Harvard Medical School, Boston, Massachusetts 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.fertnstert.2008.01.071DOI Listing
November 2008
10 Reads
2 Citations
4.590 Impact Factor

New insights into the pathogenesis of serous ovarian cancer and its clinical impact.

J Clin Oncol 2008 Nov 14;26(32):5284-93. Epub 2008 Oct 14.

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2008.18.1107DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2652087PMC
November 2008
10 Reads
125 Citations
18.430 Impact Factor

New insights into the pathogenesis of serous ovarian cancer and its clinical impact.

Levanon K, Crum C, Drapkin R, Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, vol. 26, no. 32, pp. 5284-5293

http://europepmc.org/abstract/med/18854563

View Article
November 2008
9 Reads

Does the fimbria have an embryologic origin distinct from that of the rest of the fallopian tube?

Garrett LA, Vargas SO, Drapkin R, Laufer MR, Fertility and sterility, 2008, vol. 90, no. 5, pp. 2008.e5-8

http://europepmc.org/abstract/med/18353321

View Article
November 2008
5 Reads

Regression of drug-resistant lung cancer by the combination of rosiglitazone and carboplatin.

Girnun GD, Chen L, Silvaggi J, Drapkin R, Chirieac LR, Padera RF, Upadhyay R, Vafai SB, Weissleder R, Mahmood U, Naseri E, Buckley S, Li D, Force J, McNamara K, Demetri G, Spiegelman BM, Wong KK, Clinical cancer research : an official journal of the American Association for Cancer Research, 2008, vo

http://europepmc.org/abstract/med/18927287

View Article
October 2008
8 Reads

Urokinase-type plasminogen activator receptor: a beacon of malignancy?

Clin Cancer Res 2008 Sep;14(18):5643-5

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-08-1557DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2587046PMC
September 2008
10 Reads
1 Citation
8.722 Impact Factor

Urokinase-type plasminogen activator receptor: a beacon of malignancy?

Drapkin R, Clauss A, Skates S, Clinical cancer research : an official journal of the American Association for Cancer Research, 2008, vol. 14, no. 18, pp. 5643-5645

http://europepmc.org/abstract/med/18794069

View Article
September 2008
9 Reads

Tubal and ovarian pathways to pelvic epithelial cancer: a pathological perspective.

Jarboe EA, Folkins AK, Drapkin R, Ince TA, Agoston ES, Crum CP, Histopathology, 2008, vol. 53, no. 2, pp. 127-138

http://europepmc.org/abstract/med/18298580

View Article
August 2008
15 Reads

Adenofibroma of the fimbria: a common entity that is indistinguishable from ovarian adenofibroma.

Int J Gynecol Pathol 2008 Jul;27(3):390-7

Department of Pathology, Division of Women's and Perinatal Pathology, Brigham and Women's Hospital, Boston, Massachusetts 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PGP.0b013e3181639a82DOI Listing
July 2008
25 Reads
1 Citation
1.631 Impact Factor

A novel breast cancer-associated BRIP1 (FANCJ/BACH1) germ-line mutation impairs protein stability and function.

De Nicolo A, Tancredi M, Lombardi G, Flemma CC, Barbuti S, Di Cristofano C, Sobhian B, Bevilacqua G, Drapkin R, Caligo MA, Clinical cancer research : an official journal of the American Association for Cancer Research, 2008, vol. 14, no. 14, pp. 4672-4680

http://europepmc.org/abstract/med/18628483

View Article
July 2008
9 Reads

A candidate precursor to pelvic serous cancer (p53 signature) and its prevalence in ovaries and fallopian tubes from women with BRCA mutations.

Gynecol Oncol 2008 May 14;109(2):168-73. Epub 2008 Mar 14.

The Division of Women's and Perinatal Pathology, Brigham and Women's Hospital, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2008.01.012DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2746001PMC
May 2008
16 Reads
66 Citations
3.774 Impact Factor

Use of yeast-secreted in vivo biotinylated recombinant antibodies (Biobodies) in bead-based ELISA.

Scholler N, Lowe KA, Bergan LA, Kampani AV, Ng V, Forrest RM, Thorpe JD, Gross JA, Garvik BM, Drapkin R, Anderson GL, Urban N, Clinical cancer research : an official journal of the American Association for Cancer Research, 2008, vol. 14, no. 9, pp. 2647-2655

http://europepmc.org/abstract/med/18451228

View Article
May 2008
9 Reads

A candidate precursor to pelvic serous cancer (p53 signature) and its prevalence in ovaries and fallopian tubes from women with BRCA mutations.

Folkins AK, Jarboe EA, Saleemuddin A, Lee Y, Callahan MJ, Drapkin R, Garber JE, Muto MG, Tworoger S, Crum CP, Gynecologic oncology, 2008, vol. 109, no. 2, pp. 168-173

http://europepmc.org/abstract/med/18342932

View Article
May 2008
5 Reads

A molecular signature of gastric metaplasia arising in response to acute parietal cell loss.

Gastroenterology 2008 Feb 4;134(2):511-22. Epub 2007 Dec 4.

Nashville VA Medical Center and the Department of Surgery, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.gastro.2007.11.058DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2857727PMC
February 2008
49 Reads
66 Citations
16.720 Impact Factor

A molecular signature of gastric metaplasia arising in response to acute parietal cell loss.

Nozaki K, Ogawa M, Williams JA, Lafleur BJ, Ng V, Drapkin RI, Mills JC, Konieczny SF, Nomura S, Goldenring JR, Gastroenterology, 2008, vol. 134, no. 2, pp. 511-522

http://europepmc.org/abstract/med/18242217

View Article
February 2008
7 Reads

Serous carcinogenesis in the fallopian tube: a descriptive classification.

Int J Gynecol Pathol 2008 Jan;27(1):1-9

Department of Pathology, Division of Women's and Perinatal Pathology, Brigham and Women's Hospital, Boston, Massachusetts 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/pgp.0b013e31814b191fDOI Listing
January 2008
10 Reads
65 Citations
1.631 Impact Factor

Serous carcinogenesis in the fallopian tube: a descriptive classification.

Jarboe E, Folkins A, Nucci MR, Kindelberger D, Drapkin R, Miron A, Lee Y, Crum CP, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists, 2008, vol. 27, no. 1, pp. 1-9

http://europepmc.org/abstract/med/18156967

View Article
January 2008
8 Reads

Distinctive cytogenetic profile in benign metastasizing leiomyoma: pathogenetic implications.

Am J Surg Pathol 2007 May;31(5):737-43

Department of Pathology, Divisions of Women's and Perinatal Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/01.pas.0000213414.15633.4eDOI Listing
May 2007
7 Reads
17 Citations
5.145 Impact Factor

Distinctive cytogenetic profile in benign metastasizing leiomyoma: pathogenetic implications.

Nucci MR, Drapkin R, Dal Cin P, Fletcher CD, Fletcher JA, The American journal of surgical pathology, 2007, vol. 31, no. 5, pp. 737-743

http://europepmc.org/abstract/med/17460458

View Article
May 2007
8 Reads

Lessons from BRCA: the tubal fimbria emerges as an origin for pelvic serous cancer.

Clin Med Res 2007 Mar;5(1):35-44

Department of Pathology, Brigham and Womens Hospital, 75 Francis Street, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3121/cmr.2007.702DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1855333PMC
March 2007
33 Reads
73 Citations

Lessons from BRCA: the tubal fimbria emerges as an origin for pelvic serous cancer.

Crum CP, Drapkin R, Kindelberger D, Medeiros F, Miron A, Lee Y, Clinical medicine & research, 2007, vol. 5, no. 1, pp. 35-44

http://europepmc.org/abstract/med/17456833

View Article
March 2007
11 Reads

Further evidence for BRCA1 communication with the inactive X chromosome.

Silver DP, Dimitrov SD, Feunteun J, Gelman R, Drapkin R, Lu SD, Shestakova E, Velmurugan S, Denunzio N, Dragomir S, Mar J, Liu X, Rottenberg S, Jonkers J, Ganesan S, Livingston DM, Cell, 2007, vol. 128, no. 5, pp. 991-1002

http://europepmc.org/abstract/med/17350581

View Article
March 2007
10 Reads

A recurrent mutation in PALB2 in Finnish cancer families.

Erkko H, Xia B, Nikkilä J, Schleutker J, Syrjäkoski K, Mannermaa A, Kallioniemi A, Pylkäs K, Karppinen SM, Rapakko K, Miron A, Sheng Q, Li G, Mattila H, Bell DW, Haber DA, Grip M, Reiman M, Jukkola-Vuorinen A, Mustonen A, Kere J, Aaltonen LA, Kosma VM, Kataja V, Soini Y, Drapkin RI, Livingston DM, W

http://europepmc.org/abstract/med/17287723

View Article
March 2007
7 Reads

The distal fallopian tube: a new model for pelvic serous carcinogenesis.

Curr Opin Obstet Gynecol 2007 Feb;19(1):3-9

Division of Women's and Perinatal Pathology, Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/GCO.0b013e328011a21fDOI Listing
February 2007
38 Reads
124 Citations
2.070 Impact Factor

A candidate precursor to serous carcinoma that originates in the distal fallopian tube.

Lee Y, Miron A, Drapkin R, Nucci MR, Medeiros F, Saleemuddin A, Garber J, Birch C, Mou H, Gordon RW, Cramer DW, McKeon FD, Crum CP, The Journal of pathology, 2007, vol. 211, no. 1, pp. 26-35

http://europepmc.org/abstract/med/17117391

View Article
January 2007
10 Reads

Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas.

Cancer Res 2005 Mar;65(6):2162-9

Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-04-3924DOI Listing
March 2005
54 Reads
114 Citations
9.330 Impact Factor

Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas.

Drapkin R, von Horsten HH, Lin Y, Mok SC, Crum CP, Welch WR, Hecht JL, Cancer research, 2005, vol. 65, no. 6, pp. 2162-2169

http://europepmc.org/abstract/med/15781627

View Article
March 2005
8 Reads

Dicer-deficient mouse embryonic stem cells are defective in differentiation and centromeric silencing.

Genes Dev 2005 Feb;19(4):489-501

The Dana-Farber Cancer Institute, Department of Cancer Biology, Harvard Medical School, Boston, Massachusetts 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1101/gad.1248505DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC548949PMC
February 2005
13 Reads
471 Citations
10.800 Impact Factor

Dicer-deficient mouse embryonic stem cells are defective in differentiation and centromeric silencing.

Kanellopoulou C, Muljo SA, Kung AL, Ganesan S, Drapkin R, Jenuwein T, Livingston DM, Rajewsky K, Genes & development, 2005, vol. 19, no. 4, pp. 489-501

http://europepmc.org/abstract/med/15713842

View Article
February 2005
5 Reads

Expression of candidate tumor markers in ovarian carcinoma and benign ovary: evidence for a link between epithelial phenotype and neoplasia.

Hum Pathol 2004 Aug;35(8):1014-21

Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.humpath.2004.04.014DOI Listing
August 2004
21 Reads
18 Citations
2.770 Impact Factor

Unilateral transverse arm defect with subterminal digital nubbins.

Pediatr Dev Pathol 2003 Jul-Aug;6(4):348-54

Department of Pathology, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
May 2004
42 Reads
0.860 Impact Factor

The BRCA1-associated protein BACH1 is a DNA helicase targeted by clinically relevant inactivating mutations.

Proc Natl Acad Sci U S A 2004 Feb;101(8):2357-62

Department of Cancer Biology, University of Massachusetts Medical School, Lazare Research Building, Worcester, MA 01605, USA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC356955PMC
http://dx.doi.org/10.1073/pnas.0308717101DOI Listing
February 2004
30 Reads
91 Citations
9.810 Impact Factor

The BRCA1-associated protein BACH1 is a DNA helicase targeted by clinically relevant inactivating mutations.

Cantor S, Drapkin R, Zhang F, Lin Y, Han J, Pamidi S, Livingston DM, Proceedings of the National Academy of Sciences of the United States of America, 2004, vol. 101, no. 8, pp. 2357-2362

http://europepmc.org/abstract/med/14983014

View Article
February 2004
4 Reads

Association of BRCA1 with the inactive X chromosome and XIST RNA.

Philos Trans R Soc Lond B Biol Sci 2004 Jan;359(1441):123-8

The Dana-Farber Cancer Institute and Harvard Medical School, 1 Jimmy Fund Way, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1098/rstb.2003.1371DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1693294PMC
January 2004
35 Reads
10 Citations
7.055 Impact Factor

Association of BRCA1 with the inactive X chromosome and XIST RNA.

Ganesan S, Silver DP, Drapkin R, Greenberg R, Feunteun J, Livingston DM, Philosophical transactions of the Royal Society of London. Series B, Biological sciences, 2004, vol. 359, no. 1441, pp. 123-128

http://europepmc.org/abstract/med/15065664

View Article
January 2004
2 Reads

BACH1, a novel helicase-like protein, interacts directly with BRCA1 and contributes to its DNA repair function.

Cell 2001 Apr;105(1):149-60

The Dana-Farber Cancer Institute and the Harvard, Medical School, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0092-8674(01)00304-xDOI Listing
April 2001
14 Reads
217 Citations
32.242 Impact Factor

Where transcription meets repair

Ronny Drapkin, Aziz Sancar, Danny Reinberg, 1994, 'Where transcription meets repair', Cell, vol. 77, no. 1, pp. 9-12

View Article
January 2000
4 Reads

Unilateral Transverse Arm Defect with Subterminal Digital Nubbins

Ronny I. Drapkin, David R. Genest, Lewis B. Holmes, Taosheng Huang, Sara O. Vargas, 2003, 'Unilateral Transverse Arm Defect with Subterminal Digital Nubbins', Pediatric and Developmental Pathology, vol. 6, no. 4, pp. 348-354

View Article
January 2000
3 Reads

Tubal and ovarian pathways to pelvic epithelial cancer: a pathological perspective

Elke A Jarboe, Ann K Folkins, Ronny Drapkin, Tan A Ince, Elin S Agoston, Christopher P Crum, 2009, 'Tubal and ovarian pathways to pelvic epithelial cancer: a pathological perspective', Histopathology, vol. 55, no. 5, pp. 619-619

View Article
January 2000
3 Reads

The p400 Complex Is an Essential E1A Transformation Target

Miriam Fuchs, Jill Gerber, Ronny Drapkin, Said Sif, Tsuyoshi Ikura, Vasily Ogryzko, William S. Lane, Yoshihiro Nakatani, David M. Livingston, 2001, 'The p400 Complex Is an Essential E1A Transformation Target', Cell, vol. 106, no. 3, pp. 297-307

View Article
January 2000
4 Reads

The new face of ovarian cancer modeling: better prospects for detection and treatment

Alison Karst, Ronny Drapkin, 2011, 'The new face of ovarian cancer modeling: better prospects for detection and treatment', F1000 Medicine Reports, vol. 3

View Article
January 2000
3 Reads

The multifunctional TFIIH complex and transcriptional control

Ronny Drapkin, Danny Reinberg, 1994, 'The multifunctional TFIIH complex and transcriptional control', Trends in Biochemical Sciences, vol. 19, no. 11, pp. 504-508

View Article
January 2000
3 Reads

The essential twist

Ronny Drapkin, Danny Reinberg, 1994, 'The essential twist', Nature, vol. 369, no. 6481, pp. 523-524

View Article
January 2000
3 Reads

The distal fallopian tube: a new model for pelvic serous carcinogenesis

Christopher P Crum, Ronny Drapkin, Alexander Miron, Tan A Ince, Michael Muto, David W Kindelberger, Yonghee Lee, 2007, '', Current Opinion in Obstetrics and Gynecology, vol. 19, no. 1, pp. 3-9

View Article
January 2000
2 Reads

Regulation of RNA polymerase II transcription

Ronny Drapkin, Alejandro Merino, Danny Reinberg, 1993, 'Regulation of RNA polymerase II transcription', Current Opinion in Cell Biology, vol. 5, no. 3, pp. 469-476

View Article
January 2000
6 Reads

RNA Synthesis

Ronny I Drapkin, Danny F Reinberg, 2002, 'RNA Synthesis', Encyclopedia of Life Sciences

View Article
January 2000
4 Reads

Purification of human RNA polymerase II and general transcription factors

Edio Maldonado, Ronny Drapkin, Danny Reinberg, 1996, 'Purification of human RNA polymerase II and general transcription factors', Methods in Enzymology, pp. 72-100

View Article
January 2000
4 Reads

Promoter methylation of the SALL2 tumor suppressor gene in ovarian cancers

Chang K. Sung, Dawei Li, Erik Andrews, Ronny Drapkin, Thomas Benjamin, 2013, 'Promoter methylation of the SALL2 tumor suppressor gene in ovarian cancers', Molecular Oncology, vol. 7, no. 3, pp. 419-427

View Article
January 2000
4 Reads

Primary culture and immortalization of human fallopian tube secretory epithelial cells

Alison M Karst, Ronny Drapkin, 2012, 'Primary culture and immortalization of human fallopian tube secretory epithelial cells', Nature Protocols, vol. 7, no. 9, pp. 1755-1764

View Article
January 2000
5 Reads

Pathogenesis of Ovarian Cancer

Ronny I. Drapkin, Jonathan L. Hecht, 2011, 'Pathogenesis of Ovarian Cancer', Diagnostic Gynecologic and Obstetric Pathology, pp. 758-781

View Article
January 2000
6 Reads

High Throughput Interrogation of Somatic Mutations in High Grade Serous Cancer of the Ovary

Ursula A. Matulonis, Michelle Hirsch, Emanuele Palescandolo, Eejung Kim, Joyce Liu, Paul van Hummelen, Laura MacConaill, Ronny Drapkin, William C. Hahn, 2011, 'High Throughput Interrogation of Somatic Mutations in High Grade Serous Cancer of the Ovary', PLoS ONE, vol. 6, no. 9, p. e24433

View Article
January 2000
4 Reads

Dual role of TFIIH in DNA excision repair and in transcription by RNA polymerase II

Ronny Drapkin, Joyce T. Reardon, Athar Ansari, Juch-Chin Huang, Leigh Zawel, KyuJeong Ahn, Aziz Sancar, Danny Reinberg, 1994, 'Dual role of TFIIH in DNA excision repair and in transcription by RNA polymerase II', Nature, vol. 368, no. 6473, pp. 769-772

View Article
January 2000
2 Reads

Cdk-activating kinase complex is a component of human transcription factor TFIIH

Ramin Shiekhattar, Fred Mermelstein, Robert P. Fisher, Ronny Drapkin, Brian Dynlacht, Holly C. Wessling, David O. Morgan, Danny Reinberg, 1995, 'Cdk-activating kinase complex is a component of human transcription factor TFIIH', Nature, vol. 374, no. 6519, pp. 283-287

View Article
January 2000
3 Reads

BRCA1 Supports XIST RNA Concentration on the Inactive X Chromosome

Shridar Ganesan, Daniel P. Silver, Roger A. Greenberg, Dror Avni, Ronny Drapkin, Alexander Miron, Samuel C. Mok, Voahangy Randrianarison, Steven Brodie, Jennifer Salstrom, Theodore P. Rasmussen, Ann Klimke, Christine Marrese, York Marahrens, Chu-Xia Deng, Jean Feunteun, David M. Livingston, 2002, 'B

View Article
January 2000
4 Reads

BACH1, a Novel Helicase-like Protein, Interacts Directly with BRCA1 and Contributes to Its DNA Repair Function

Sharon B. Cantor, Daphne W. Bell, Shridar Ganesan, Elizabeth M. Kass, Ronny Drapkin, Steven Grossman, Doke C.R. Wahrer, Dennis C. Sgroi, William S. Lane, Daniel A. Haber, David M. Livingston, 2001, 'BACH1, a Novel Helicase-like Protein, Interacts Directly with BRCA1 and Contributes to Its DNA Repair

View Article
January 2000
4 Reads

Adenofibroma of the Fimbria: A Common Entity That Is Indistinguishable From Ovarian Adenofibroma

Veerle Bossuyt, Fabiola Medeiros, Ronny Drapkin, Ann K. Folkins, Christopher P. Crum, Marisa R. Nucci, 2008, '', International Journal of Gynecological Pathology, vol. 27, no. 3, pp. 390-397

View Article
January 2000
4 Reads

The RNA polymerase II general transcription factors: past, present, and future.

Cold Spring Harb Symp Quant Biol 1998 ;63:83-103

Howard Hughes Medical Institute, Department of Biochemistry, Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, Piscataway 0885, USA.

View Article

Download full-text PDF

Source
July 1999
7 Reads
19 Citations

Immunoaffinity purification of the human multisubunit transcription factor IIH.

J Biol Chem 1998 Mar;273(12):7134-40

Howard Hughes Medical Institute, Division of Nucleic Acid Enzymology, Department of Biochemistry, Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, Piscataway, New Jersey 08854-5635, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1074/jbc.273.12.7134DOI Listing
March 1998
8 Reads
7 Citations
4.573 Impact Factor

Immunoaffinity purification of the human multisubunit transcription factor IIH.

LeRoy G, Drapkin R, Weis L, Reinberg D, The Journal of biological chemistry, 1998, vol. 273, no. 12, pp. 7134-7140

http://europepmc.org/abstract/med/9507027

View Article
March 1998
5 Reads

The RNA polymerase II general transcription factors: past, present, and future.

Reinberg D, Orphanides G, Ebright R, Akoulitchev S, Carcamo J, Cho H, Cortes P, Drapkin R, Flores O, Ha I, Inostroza JA, Kim S, Kim TK, Kumar P, Lagrange T, LeRoy G, Lu H, Ma DM, Maldonado E, Merino A, Mermelstein F, Olave I, Sheldon M, Shiekhattar R, Zawel L, Cold Spring Harbor symposia on quantita

http://europepmc.org/abstract/med/10384273

View Article
January 1998
4 Reads

RNA polymerase II stalled at a thymine dimer: footprint and effect on excision repair.

Nucleic Acids Res 1997 Feb;25(4):787-93

Department of Biochemistry and Biophysics, University of North Carolina School of Medicine, Chapel Hill 27599, USA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC146523PMC
http://dx.doi.org/10.1093/nar/25.4.787DOI Listing
February 1997
10 Reads
51 Citations
9.112 Impact Factor

Purification of human RNA polymerase II and general transcription factors.

Methods Enzymol 1996 ;274:72-100

Department of Biochemistry, Howard Hughes Medical Institute, Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, Piscataway 08854, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0076-6879(96)74009-0DOI Listing
February 1997
7 Reads
34 Citations
2.090 Impact Factor

RNA polymerase II stalled at a thymine dimer: footprint and effect on excision repair.

Selby CP, Drapkin R, Reinberg D, Sancar A, Nucleic acids research, 1997, vol. 25, no. 4, pp. 787-793

http://europepmc.org/abstract/med/9016630

View Article
February 1997
4 Reads

Human cyclin-dependent kinase-activating kinase exists in three distinct complexes.

Proc Natl Acad Sci U S A 1996 Jun;93(13):6488-93

Howard Hughes Medical Institute, Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, Piscataway, 088854-5635, USA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC39050PMC
http://dx.doi.org/10.1073/pnas.93.13.6488DOI Listing
June 1996
9 Reads
36 Citations
9.810 Impact Factor

Human cyclin-dependent kinase-activating kinase exists in three distinct complexes.

Drapkin R, Le Roy G, Cho H, Akoulitchev S, Reinberg D, Proceedings of the National Academy of Sciences of the United States of America, 1996, vol. 93, no. 13, pp. 6488-6493

http://europepmc.org/abstract/med/8692842

View Article
June 1996
3 Reads

A human RNA polymerase II complex associated with SRB and DNA-repair proteins.

Nature 1996 May;381(6577):86-9

Howard Hughes Medical Institute, Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, Piscataway 08854-5635, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/381086a0DOI Listing
May 1996
11 Reads
120 Citations
42.351 Impact Factor

A human RNA polymerase II complex associated with SRB and DNA-repair proteins.

Maldonado E, Shiekhattar R, Sheldon M, Cho H, Drapkin R, Rickert P, Lees E, Anderson CW, Linn S, Reinberg D, Nature, 1996, vol. 381, no. 6577, pp. 86-89

http://europepmc.org/abstract/med/8609996

View Article
May 1996
3 Reads

The Epstein-Barr virus nuclear protein 2 acidic domain forms a complex with a novel cellular coactivator that can interact with TFIIE.

Mol Cell Biol 1995 Sep;15(9):4735-44

Department of Medicine, Harvard University, Boston, Massachusetts 02115, USA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC230717PMC
http://dx.doi.org/10.1128/mcb.15.9.4735DOI Listing
September 1995
38 Reads
87 Citations
4.780 Impact Factor

The Epstein-Barr virus nuclear protein 2 acidic domain forms a complex with a novel cellular coactivator that can interact with TFIIE.

Tong X, Drapkin R, Yalamanchili R, Mosialos G, Kieff E, Molecular and cellular biology, 1995, vol. 15, no. 9, pp. 4735-4744

http://europepmc.org/abstract/med/7651391

View Article
September 1995
2 Reads

The 62- and 80-kDa subunits of transcription factor IIH mediate the interaction with Epstein-Barr virus nuclear protein 2.

Proc Natl Acad Sci U S A 1995 Apr;92(8):3259-63

Department of Medicine and Microbiology and Molecular Genetics, Harvard Medical School, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC42145PMC
http://dx.doi.org/10.1073/pnas.92.8.3259DOI Listing
April 1995
10 Reads
54 Citations
9.810 Impact Factor

The 62- and 80-kDa subunits of transcription factor IIH mediate the interaction with Epstein-Barr virus nuclear protein 2.

Tong X, Drapkin R, Reinberg D, Kieff E, Proceedings of the National Academy of Sciences of the United States of America, 1995, vol. 92, no. 8, pp. 3259-3263

http://europepmc.org/abstract/med/7724549

View Article
April 1995
5 Reads

Cdk-activating kinase complex is a component of human transcription factor TFIIH.

Nature 1995 Mar;374(6519):283-7

Howard Hughes Medical Institute, Department of Biochemistry, Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, Piscataway 08854-5635.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/374283a0DOI Listing
March 1995
8 Reads
127 Citations
42.351 Impact Factor

The multifunctional TFIIH complex and transcriptional control.

Trends Biochem Sci 1994 Nov;19(11):504-8

Howard Hughes Medical Institute, Department of Biochemistry, Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, Piscataway 08854-5635.

View Article

Download full-text PDF

Source
November 1994
11 Reads
32 Citations
11.230 Impact Factor

Transcription. The essential twist.

Nature 1994 Jun;369(6481):523-4

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/369523a0DOI Listing
June 1994
13 Reads
42.351 Impact Factor

Where transcription meets repair.

Cell 1994 Apr;77(1):9-12

Department of Biochemistry, Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, Piscataway 08854.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/0092-8674(94)90228-3DOI Listing
April 1994
10 Reads
37 Citations
32.242 Impact Factor

Dual role of TFIIH in DNA excision repair and in transcription by RNA polymerase II.

Nature 1994 Apr;368(6473):769-72

Department of Biochemistry, Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, Piscataway 08854-5635.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/368769a0DOI Listing
April 1994
11 Reads
137 Citations
42.351 Impact Factor

Regulation of RNA polymerase II transcription.

Curr Opin Cell Biol 1993 Jun;5(3):469-76

Department of Biochemistry, Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, Piscataway 08854-5635.

View Article

Download full-text PDF

Source
June 1993
10 Reads
29 Citations
8.470 Impact Factor

Top co-authors

Michelle S Hirsch
Michelle S Hirsch

Brigham and Women's Hospital

17
Alison M Karst
Alison M Karst

Dana-Farber Cancer Institute

12
Christopher P Crum
Christopher P Crum

Brigham and Women's Hospital

11
Joyce F Liu
Joyce F Liu

Dana-Farber Cancer Institute

10
Huiying Piao
Huiying Piao

Dana-Farber Cancer Institute

8
Douglas A Levine
Douglas A Levine

Memorial Sloan Kettering Cancer Center

8
Kevin M Elias
Kevin M Elias

Brigham and Women's Hospital

7
Dariush Etemadmoghadam
Dariush Etemadmoghadam

University of Melbourne

7
Ursula A Matulonis
Ursula A Matulonis

Dana-Farber Cancer Institute

7

Followers

Kylie L Gorringe
Kylie L Gorringe

Peter MacCallum Cancer Centre